FAQ

Aplindore

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2009
01220062009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
The dopamine D2 receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with l-dopa
Dopamine replacement therapy in Parkinson’s disease (PD) using l-dopa is invariably associated with a loss of drug efficacy… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2009
Review
2009
Novel therapeutic strategies in Parkinson’s disease
PD is a neurodegenerative disorder triggered by genetic and/or environmental factors and the pathological processes begin many… (More)
  • figure 1
  • table 1
Is this relevant?
2006
2006
Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.
The pharmacology of aplindore (DAB-452) was characterized in CHO-K1 cells stably transfected with the human dopamine D(2… (More)
Is this relevant?
2006
2006
Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor.
BACKGROUND AND PURPOSE Low efficacy partial agonists at the D2 dopamine receptor may be useful for treating schizophrenia. In… (More)
Is this relevant?